Table 1.

Variables and key information, measurements and implementation instruments and data collection method in the SCUBY project.

	RQ	Variables and key information	Measurement/implementation instruments	Data collection method
	Formative phase
	Macro-level: Context analysis
1a	What is the current strategy, capacity and engagement of stakeholders to scale-up the ICP and what is the societal and health system context that are potential barriers or facilitators to scale-up?	Current strategy and plans to scale-up ICP; national context/health system barriers and facilitators	Study specific semi-structured interview guide	Indepth interview and document analysis
1b	Who are the key stakeholders in the scale-up?	Stakeholder mapping and power and interest analysis	Guidelines for Conducting a Stakeholder Analysis	Indepth interview and document analysis
1c	What is the financing system for ICP?	Financing system for ICP	Topic guide on health and diabetes financing	Key informant interviews, policy and administraion documents, related studies national health accounty
	Meso-level: Analysis of current ICP implementation and cost	Analysis of current ICP implementation and cost
1d	What is the present implementation of the ICP and (variation in) organisational models in the current pilot sites	Implementation of the ICP; organisational models and organisation context	ICP implementation assessment grid; focus group discussion guide	researcher observation and interviews in selected pilot sites
1e	What are the costs of implementing the ICP from the health system and health provider perspective	Provider-side costs of ICP	Study specific costing tool	national health accounts and health insurance data (Slov/Bel), existing lit, rapid health facility survey (Cam)
	Micro-level: individual outcomes	Outcomes at individual level
1f	What are the outcomes of the ICP as currently implemented	Number of people with T2D/HTN; Proportion of people tested/diagnosed/retained in care/on treatment/followed-up/well controlled	Cascades of care, starting from prevalence in reference year.	household survey (Cam), combination of databases from insurance, laboratories and primary care networks (Slo,Bel)
1g	What is the cost for the patient and what are barriers to care?	Patient side barriers to care; patient out of pocket expenditure	Study specific demand side costing tool	qualitative through focus group and indepth interview with patients; quantitative through patient diaries for sample of patients through population based survey
	Intervention phase: scale-up strategy and implementation
	Roadmaps	Scale-up strategy
2a	How can we, in co-creation with stakeholders, optimize the current Scale-Up (S-U) strategy	Recommendations for improved scale up	Policy dialogues and roadmaps	Formative findings study 1–3
2b	Which mechanisms can be identified for the relationship between scale-up strategy, actors and context?	Empirical and theoretical evidence	Scientific enquiry	dialogue practice and theory, implementors and researchers
2c	What is the minimum indicator set to monitor	minimum monitoring data set	quantitative data on CoC; qualitative data on process, barriers and context	survey statistics extracted from routine data; observations, key information interviews, patient interviews, project documents
2d	What are the projected cost for different scenarios	projected cost	costing models	Formative findings study 1–3
	Evaluation phase: outcome and impact evaluation
3a	How has the roadmap been implemented and to what extent, and how is the context influencing the implementation of the scale-up strategies, including cost	implementation of the roadmap	Reach (Number of scaleable units covered by the scale-up); Acceptability (measured by Affective Attitude, Burden, perceived effectiveness, Opportunity Costs, Intervention Coherence, implementors’ Self-efficacy, and Ethicality) and feasibility of the scale-up strategy (measured by adaptation and fidelity of implementation)	project diaries, interviews with implementors and key informant interviews
3b	What is the progress on each of the three axes of the scale-up box	progress on (a) the population coverage(b) the expansion of the ICP (c) integration	(a) reach; target population living in area; number of people actually covered by intervention (b) number of components added to the ICP (c1 organisation level, ICP implementation grid see 2) normalisation process theory (c2health system level) sustainable financing arrangements for the ICP, provider payment mechanisms stimulate health education and self-management, human resource planning for teamwork in facilities and with community, care pathways, common monitoring	Quantitative data through routine data or population survey. Qualitative data at endline through project diaries, interviews with implementors, and key informant interviews and practice
3c	What is the impact of the scale-up on the control of T2D and HT ?	impact of the scale-up on the control of T2D and HT	CoC (see 3)	Interrupted timeseries from routine data
3d	What are the costs of the scaled-up ICP, for the health system and for the patient?	costs of the scaled-up ICP: (a) health system and (p) patient perspectove	(a) cost of human resources and service delivery (b) out of pocket expenditure (see 3)	(a) primary qualitative and quantitative data (b) patient survey